ReNAgade Therapeutics develops RNA-based therapeutics to target and treat various diseases at the genetic level. By harnessing the unique properties of RNA, the company aims to provide precise interventions that address the underlying causes of genetic disorders.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FVFounders
Product
Problem
Many diseases have a genetic basis, but traditional treatments often address symptoms rather than the underlying genetic cause. Developing targeted therapies that can precisely modify or repair faulty genes remains a significant challenge.
Solution
ReNAgade Therapeutics is developing RNA-based therapeutics designed to target and treat diseases at the genetic level. By leveraging the unique properties of RNA, the company aims to create precise interventions that address the root causes of genetic disorders. Their approach focuses on developing therapies that can selectively modulate gene expression or correct genetic defects, offering the potential for more effective and durable treatments.
Target Audience
The primary target audience includes patients suffering from genetic disorders and the healthcare providers who treat them.
Features
- RNA-based therapeutics for targeted gene modulation
- Development of therapies addressing the underlying causes of genetic disorders
- Precise interventions to selectively modify gene expression
- Potential for more effective and durable treatments compared to traditional approaches